PT  - JOURNAL ARTICLE
AU  - Edward B. Silberstein
TI  - Prevalence of Adverse Events to Radiopharmaceuticals from 2007 to 2011
AID  - 10.2967/jnumed.114.138057
DP  - 2014 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1308--1310
VI  - 55
IP  - 8
4099  - http://jnm.snmjournals.org/content/55/8/1308.short
4100  - http://jnm.snmjournals.org/content/55/8/1308.full
SO  - J Nucl Med2014 Aug 01; 55
AB  - We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. Methods: Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007–2011. Results: 1,024,177 radiopharmaceutical administrations were monitored: 207,281 diagnostic PET, 803,696 diagnostic non-PET, and 13,200 therapeutic. In addition, 112,830 adjunctive nonradioactive pharmaceutical administrations were monitored. The annual use of bone scintigraphy and radiotracer therapies was unchanged. PET radiopharmaceutical use increased from 17% to 26% of diagnostic procedures (P < 0.01). The incidence of radiopharmaceutical AEs was 2.1/105 administrations, with no hospitalizations or deaths. Conclusion: From 2007 to 2011, PET studies increased, and therapeutic radiopharmaceutical use and bone scintigraphy were unchanged. Over 2 decades, the incidence of AEs has remained stable at 2.1–2.3/105 dosages.